Clovis reports interim Phase II in PARP race

Clovis Oncology Inc. (NASDAQ:CLVS) reported initial data from the Phase II ARIEL2 trial of rucaparib ( CO-338) to treat platinum-sensitive, relapsed ovarian cancer. The biotech suggested combining tumor BRCA1/2 mutation status with genomic loss of heterozygosity (LOH) analysis may help predict which patients are likely to benefit from the oral inhibitor of poly(ADP-ribose) polymerase-1 ( PARP-1) and PARP-2.

Patients were identified as BRCA mutant, wild-type BRCA with high genomic LOH or biomarker negative. Patients with the BRCA mutation had a 70% overall response rate compared to 40% in wild-type BRCA patients with high genomic LOH and 8% in biomarker negative patients. Overall response was defined by RECIST criteria and a CA-125 response. ...